Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice

Tolerance without Clonal Expansion: Self-Antigen-Expressing B Cells Program Self-Reactive T Cells for Future Deletion

(2014) F. Frommer et al.   JOURNAL OF IMMUNOLOGY

Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane

(2014) S. E. James et al.   JOURNAL OF IMMUNOLOGY

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Peripheral CD8+ T Cell Tolerance to Self-Proteins Is Regulated Proximally at the T Cell Receptor

(2008) Ryan M. Teague et al.   IMMUNITY

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

(2008) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab

(2008) Roy M. Fleischmann   SEMINARS IN ARTHRITIS AND RHEUMATISM